Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This it the RNS for me, that was a game changer just prior to the results.
Even RR had to start its recovery somewhere...
https://www.lse.co.uk/rns/OXB/update-on-cdmo-services-kkuod0ei8hi7occ.html
20 Mar 2024 07:00
RNS Number : 4894H
Oxford Biomedica PLC
20 March 2024
Oxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement
- New and expanded contracts highlight commercial momentum across all viral vector types
- OXB now working on multiple late-stage programmes with its portfolio of client programmes progressing to later stage work
Oxford, UK - 20, March, 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity.
Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. As a result of commercial developments set out below, OXB is now working on three late-stage programmes.
Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based manufacturing facility.
Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing.
Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV).
Under the terms of these agreements, Oxford Biomedica will receive payments related to the development and manufacturing of viral vectors for use in clinical trials in addition to certain development and regulatory milestone payments. These payments will support the Company in achieving its medium-term financial guidance announced on 5 March 2024.
Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: "The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients' confidence in OXB's ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our c
Thanks. I do look at ADFN daily as well.
Try ADVFN…Plenty of chat over there. Not sure whether this board is perhaps still in a state of shock after the horrendous past couple of years.
After a 50% rise this month -- will be interesting to see.
So quiet on this BB. Seems a lot of invididual investors are not following this one.
ABL Europe could be buying shares of course
https://www.globenewswire.com/en/news-release/2024/01/29/2818732/0/en/Oxford-Biomedica-completes-acquisition-of-ABL-Europe.html
Off we go again, another late rise
The small breakout has now solidified and the results taken well. Been a good few days for me - for a change!
Added up.
1515p to such a drop is unjustified.
Overhead supply from previous trading at 241.5. The sp, at 250, is above the resistance level, of 241.5, thus reversing the resistance level to become support. The only obvious remaining overhead supply area, is at 300, so that is the projected price target for profit. The underlying sector is bullish, providing general support to OXB. DYOR.
Et voila! *** Takes a bow ****
A small breakout at last it seems, has taken some time and patience
Let's hope so. I only have a small amount of shares, I was tempted to add more when were at the top a few years ago, thankfully I didn't, this has been a rough ride.
To say the recovery is underway here. Back over 200pwhich could have been a psychological barrier. I have been accumulating recently so will be happy if the climb continues.
Back to where we were before the announcement. That burst of optimism didn't last long.
Bought more as well to reduce my average to £6.44. Very much doubt I will see that again. Should have sold when Shatter did or better still at £15!
When will I learn?
Pretty steep for a company that looks like it is in recovery mode! Maybe profit taking after the recent jump? I am still a buyer.
It's a bit of a shame OXB sold off their best asset, the site they owned. Novo acquired Catalent in the US for a big premium largely for their manufacturing capacity.
Looks like the market is struggling to find those willing to sell.
Yep, but going in the right direction. I only bought in this last week. Hopefully, there will be a steady rise but it is a long-term hold, which should reap decent returns by end of 2025.
This looks like good news though there is still a long way to go but b/e next year hopefully means an increasing sp instead of the perpetual drops we have been getting..
Still holding.
I might correct you there. Cutting edge science is what drives biotechnological and medical R&D forward. OXB used to be in the perfect spot where their manufacturing could have financed their internal product development. Imagine if they had invested the vaccine money into the next CAR-T therapy without having the need to knock on the door of VCs. Now it is a stagnating business, they can only make money if other companies investing in cutting edge science bring them something to make. They are also competing with much bigger and more established lentiviral product manufactures, that can probably do it faster, cheaper and better.
Money and Science, I was just making this point with my friend over the phone, OXB under Dawson before 2020, had a drug discovery group that was outlicensing clinical stage vectors for millions, a cell line and vilral vector development group, process innovation team and a profitable manufacturing CDMO. You wouldn't imagine that version of OXB with Dawson would be where it is today if we skipped the Astra Zeneca vaccine saga because they were already headed places.
Cutting edge research is all well and good but doesn’t pay the bills. The vaccine was a one off ( hopefully) but it may take years and some thought to make this company profitable !
Does not seem the case. However, it makes me wonder why they have gone through such a big restructuring to then perform significantly worse than the previous management. The previous team had a successful delivery of the vaccine, was bringing in clients and supporting world-class R&D. Now that they are a pure-play CDMO, they only seem to be able to sink the share price.